Global Medical Imaging Agents Market 2019-2026: Production of Radiopharmaceuticals from Cyclotrons Presents Opportunities
Oct 30, 2019, 08:00 ET
DUBLIN, Oct. 30, 2019 /PRNewswire/ -- The "Medical Imaging Agents Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The Medical imaging agents market is expected to grow at mid-single-digit CAGR from 2019 to 2026 to reach $12,290.7 million by 2026.
Medical imaging agents global market by molecule/isotope segmented into contrast agents and nuclear medicine. According to the author, the contrast agents' global market is expected to grow at a mid-single-digit CAGR from 2019 to 2026.
Iodine-based contrast agents market held the largest market revenue in 2019 and the microbubble segment is the fastest-growing segment at double-digit CAGR from 2019 to 2026 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic.
Non-Ionic Iodine-based contrast agents market accounted for the largest share in 2019. Non-ionic iodine contrast agents are used more because of lower osmolality, they are better tolerated and another advantage is that they appear to have less toxicity. Ionic Iodine based contrasts are further segmented by its chemical structure into monomers and dimers.
Monomers market accounted for the largest share in 2019. Non-Ionic Iodine based contrasts are further segmented by its chemical structure into monomeric and dimeric. Monomerics market accounted for the largest share in 2019 and is projected to grow at a low single-digit CAGR from 2019 to 2026 as they are safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity.
Key Topics Covered:
1 Executive Summary
2 Introduction
3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Increasing Demand For Imaging Agent-Assisted Diagnostic Procedures
3.3.1.2 Production Of Radiopharmaceuticals From Cyclotrons
3.3.1.3 The Growth Of Medical Imaging Technologies In Emerging Markets
3.3.1.4 Usage Of Hybrid Imaging
3.3.1.5 Favorable Reimbursement
3.3.2 Restraints And Threats
3.3.2.1 Side Effect Associated With Medical Imaging Agents
3.3.2.2 The Shorter Half-Life Of Radiopharmaceuticals
3.3.2.3 Shortage Of Radiologist And Qualified Technicians
3.3.2.4 High Cost And Supply Shortage Of Isotopes
3.3.2.5 Stringent Regulations For Manufacturing And Marketing Of Medical Imaging Agents
3.4 Regulatory Guidelines
3.5 Reimbursement Table
3.6 Upcoming Technology
3.6.1 Near-Infrared Fluorescent Imaging
3.6.2 Targeted Contrast Agent
3.7 Clinical Trials
3.7.1 Contrast Agents Clinical Trial
3.7.1.1 Gadolinium Based Contrast Agents
3.7.1.2 Iodinated Contrast Agents
3.7.1.3 Iron Oxide Contrast Agents
3.7.1.4 Manganese Based Contrast Agents
3.7.2 Nuclear Medicine Clinical Trials
3.7.2.1 Pet Based Imaging Agents (Fdg)
3.7.2.2 F-18 Based Agents
3.7.2.3 Xe-133 Based Agents
3.7.2.4 Ga-68 Based Agents
3.8 Supply Chain Analysis Of Nuclear Medicine
3.8.1 Reactors
3.8.2 Processing Facility
3.8.3 Generators Manufacturing Units
3.8.4 Hospitals And Central Radio Pharmacies
3.9 List Of Current Irradiators And Processors Of Technitum 99
3.10 Supply Chain Analysis Of Contrast Agents
3.11 Patent Trends
3.12 Porter's Five Force Analysis
3.13 Market Share Analysis
3.13.1 Market Share Analysis By Major Players
3.13.2 Market Share Analysis Of Contrast Agents
3.13.3 Market Share Analysis Of Nuclear Medicine
3.13.4 Market Share Analysis Of Mri
3.13.5 Market Share Analysis Of X-Ray/Ct
3.13.6 Market Share Analysis Of Ultrasound Agents
3.13.7 Market Share Analysis Of Spect Agents
3.13.8 Market Share Analysis Of Pet Agents
3.14 Medical Imaging Agents Global Consumption Data
3.14.1 X-Ray/Ct Global Comsumption Volume
3.14.2 Mri Global Comsumption Volume
3.14.3 Ultrasound Global Comsumption Volume
3.15 Medical Imaging Procedural Volume
3.15.1 X-Ray/Ctcontrast Agents Global Procedural Volume
3.15.2 Mri Contrast Agents Global Procedural Volume
3.15.3 Ultrasound Contrast Agents Global Procedural Volume
4 Medical Imaging Agents Global Market, By Molecule/Isotope
4.1 Introduction
4.2 Contrast Agents
4.2.1 Iodinated Contrast Agents
4.2.1.1 Iodinated Ionic Contrast Agents
4.2.1.1.1 Monomers
4.2.1.1.2 Dimer
4.2.1.2 Iodinated Non-Ionic Contrast Agents
4.2.1.2.1 Monomer
4.2.1.2.2 Dimer
4.2.2 Gadolinium-Based Contrast Agents
4.2.2.1 Macrocyclic Contrast Agents
4.2.2.1.1 Ionic Macrocyclic Contrast Agents
4.2.2.1.2 Non-Ionic Macrocyclic Contrast Agents
4.2.2.2 Linear Gadolinium Based Contrast Agents
4.2.2.2.1 Ionic Linear Contrast Agents
4.2.2.2.2 Non-Ionic Linear Contrast Agents
4.2.3 Microbubble Based Contrast Agents
4.2.4 Others Contrast Agents
4.3 Nuclear Medicine
4.3.1 Technetium (Tc-99M)
4.3.2 Thallium (Tl-201)
4.3.3 Gallium (Ga-67)
4.3.4 Iodine (I-123)
4.3.5 Xenon (Xe-133)
4.3.6 Samarium (Sm-153)
4.3.7 Rhenium (Re-186)
4.3.8 Fluorodeoxyglucose (18F-Fdg)
4.3.9 Gallium (Ga-68)
4.3.10 Rubidium (Rb-82)
4.3.11 Others
5 Medical Imaging Agents Global Market, By Modality
5.1 Introduction
5.2 X-Ray/Computed Tomography (Ct)
5.3 Magnetic Resonance Imaging (Mri)
5.4 Ultrasound
5.5 Single Photo Emission Computed Tomography (Spect)
5.6 Positron Emission Tomography(Pet)
6 Medical Imaging Agents Global Market, By Application
6.1 Introduction
6.2 Cardiovascular
6.3 Cancer
6.4 Gastrointestinal
6.5 Musculoskeletal
6.6 Neurology
6.7 Nephrology
6.8 Obstetrics And Gynecology
6.9 Pulmonary
6.10 Hepatology
6.11 Others
7 Medical Imaging Agents Global Market, By Route Of Administration
7.1 Introduction
7.2 Intravascular
7.3 Oral
7.4 Rectal
7.5 Others
8 Medical Imaging Agents Global Market, By Imaging
8.1 Introduction
8.2 Diagnostic Imaging
8.3 Interventional Imaging
9 Medical Imaging Agents Global Market, By End-Users
9.1 Introduction
9.2 Hospital
9.3 Diagnostic & Ambulatory Surgical Centers
9.4 Other End-User
10 Regional Analysis
11 Competitive Landscape
11.1 Introduction
11.2 Collaborations, Agreements And Partnership
11.3 Approvals
11.4 Other Key Development
12 Major Player Profiles
- Bayer Group
- Bracco Group
- Cardinal Health Inc.
- Curium Pharma
- Fujifilm Holdings Corporation
- Fujipharma Co Ltd
- GE Company (Ge Healthcare)
- Guerbet
- Jubilant Lifesciences
- Lantheus Medical Imaging Inc.
- Novartis (Advance Accelerator Applications S.A.)
Other Companies Mentioned
- Avid Radiopharmaceuticals, Inc (Eli Lilly and Company)
- Advanced Accelerator Applications Sa (Novartis Co.)
- Arronax-Nantes
- Australian Nuclear Science and Technology Organization
- Bayer Group
- Beijing Beilu Pharmaceuticals Company Limited
- Biem Pharmaceuticals
- Bracco Imaging S.P.A.
- BV Cyclotron
- Canadian Isotope Innovations Corp.
- Cardinal Health
- Center of Molecular Research
- Centre For Probe Development And Commercialization
- China National Nuclear Corporation (China Isotope & Radiation Corporation)
- Curium Pharma
- Daihan Pharma Co Ltd
- Dongkook Lifescience
- Eckert & Ziegler Strahlen
- Eczacibasi-Monrol Nuclear Products
- Fluoro Pharma
- Fujifilm Corporation
- Fujipharma Co Ltd
- Futurechem Co. Ltd
- Galenica Senese S.R.L
- GE Healthcare
- Graton Pharma
- Guerbet
- Hana Pharm Co., Ltd
- Harmony Life Sciences
- Huayi Technology Co., Ltd (Huayi Isotopes Co)
- Imax Diagnostic Imaging Limited
- Institute Of Isotopes
- International Isotopes Inc.
- Iso-Analytical Ltd.
- Isorad Ltd
- Iso-Tex Diagnostics Inc.
- Isotopia Molecular Imaging Ltd.
- I-Themba Labs
- JB Chemicals And Pharmaceuticals Ltd
- Jodas Expoim Pvt. Ltd
- JSC Isotope
- Jubilant Lifescience
- Lantheus Medical Imaging
- Magnus Health
- Medical Isotopes
- Nano Therapeutics
- National Institute For Radioelements (Ire)
- Nihon Medi Physics Co Ltd
- Nuclear Research And Consultancy Group (Nrg)
- Otsuka Pharmaceutical Co., Ltd
- Pars Isotope
- Perma-Fix Medical S.A.
- Pharmalucence Inc.
- Rege Imaging & Cinefilms Private Limited
- Rotop Pharmaka Gmbh
- Samyoung Unitech
- Sanochemia
- Shine Medical Technologies, Inc
- Solcom Limited
- South African Nuclear Energy Corporation (Ntp Radioisotopes Soc Ltd)
- Stryker(Novadaq Technologies)
- Swan Isotopen AG
- Taejoon Pharm Co. Ltd.,
- Trivitron Healthcare
- Unijules Life Sciences Ltd
- Unimark Remedies
- Zag Zyklotron AG
- Zhejiang Starry Pharma
For more information about this report visit https://www.researchandmarkets.com/r/3zfbe8
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
